novel oral polio vaccine type 2 (nopv2)
Vaccineexperimental
Clinical trial activity
5 trials · 9 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started Sep 21, 2020 (NCT04693286)
Timeline
Indications
Studied for
Mechanism of action
- PoliovirusImmunity, active
Poliovirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06895486 | Phase 2 | Sep 29, 2025 | Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention (CDC), Cevaxin, PATH, PT Bio Farma, Technical Resources International, Inc. (TRI) |
| NCT06137664 | Phase 1/Phase 2 (Phase 2) | Dec 29, 2023 | PATH |
| NCT05166031 | Phase 3 | Dec 31, 2020 | Bill and Melinda Gates Foundation, Fidec Corporation |
| NCT04579510 | Phase 2 | Oct 11, 2020 | Centers for Disease Control and Prevention (CDC), International Center for Diarrheal Disease Research |
| NCT04693286 | Phase 2 | Sep 21, 2020 | Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention (CDC), International Center for Diarrheal Disease Research, PATH, PT Bio Farma, World Health Organization |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (9)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bill and Melinda Gates Foundation | Academic/Hospital | 3 | 0 | 2 | 2020 |
| Centers for Disease Control and Prevention (CDC) | Government | 3 | 1 | 1 | 2020 |
| PATH | Academic/Hospital | 3 | 2 | 1 | 2020 |
| International Center for Diarrheal Disease Research | Academic/Hospital | 2 | 1 | 1 | 2020 |
| PT Bio Farma | For profit | 2 | 0 | 1 | 2020 |
| Cevaxin | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Fidec Corporation | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Technical Resources International, Inc. (TRI) | For profit | 1 | 0 | 1 | 2025 |
| World Health Organization | Government | 1 | 0 | 1 | 2020 |
9 organizations
Page 1 / 1